The DOI matches its Crossref record.
Bariatric Interventions in Craniopharyngioma Patients—Best Choice or Last Option for Treatment of Hypothalamic Obesity?
Abstract
Although craniopharyngiomas are of low-grade histological quality and have good prognosis in terms of overall survival, long-term survivors frequently suffer from severe morbidity due to hypothalamic lesions (1). Imbalances of thirst and hunger-satiety feelings, problems of psychosocial behavior, disturbed circadian rhythm, reduced energy expenditure, pituitary deficits, and dysregulation of temperature are caused by disease and/or treatment-related hypothalamic lesions. Affected patients are at great risk for developing hypothalamic disorders of body composition such as obesity and cachexia, with comorbidities leading to premature mortality (2). Cachexia and severe weight loss due to diencephalic syndrome can occur as a rare hypothalamic disturbance of body composition in craniopharyngioma patients with hypothalamic damage. Diencephalic syndrome and cachexia at the time of craniopharyngioma diagnosis are rare (4%; ie, 21 of 485 cases recruited in KRANIOPHARYNGEOM 2000/2007). However, also in craniopharyngioma patients with diencephalic syndrome, subsequent weight gain and obesity were observed during long-term follow-up (3). Tumor- and/or treatment-associated lesions of specific posterior hypothalamic areas (ie, the mammillary bodies and the area beyond) are risk factors for the development of severe obesity and reduced long-term quality of life. A combination of hypothalamus-sparing surgical intervention and irradiation, preferably by proton beam therapy, has been shown to be effective in control of residual craniopharyngioma associated with less hypothalamic morbidity. Long-term outcome data after proton beam therapy are rare, due to the restricted availability of proton beam therapy to only few centers. The advantages of proton beam therapy based on physical characteristics of proton beam radiation include improved conformation of dose to the target volume, reduction of integral dose and of secondary neutrons, and lower risk of second malignancies by sparing of critical structures. The morbid obesity in craniopharyngioma patients with hypothalamic involvement/lesion is the result of impairment in satiety regulation, a reduced level of energy expenditure, and a downregulation of sympathetic activity. Due to this, craniopharyngioma patients develop an overactivation of their parasympathetic systems, which leads to increased daytime sleepiness, disturbed temperature regulation, and reduced heart rate. Hypothalamic obesity is mostly unresponsive to conventional interventions, such as lifestyle modifications. Accordingly, pharmacological interventions might have beneficial effects on the degree of obesity. Reported pharmacotherapeutic interventions for hypothalamic obesity include antidiabetic agents (metformin, diazoxide, fenofibrate), central stimulating agents (dextro-amphetamine, methylphenidate), hypothalamic-pituitary substitution therapy (recombinant growth hormone, thyroxine, hydrocortisone), and others, such as oxytocin or somatostatin analogues (octreotide). The reported effects are often transient and generally modest. Due to the lack of randomized controlled trials, there is currently no consensus on pharmacotherapy of hypothalamic obesity in craniopharyngioma patients. Several surgical techniques of bariatric interventions such as sleeve gastrectomy (SG), laparoscopic adjustable gastric banding (LAGB), biliopancreatic diversion, gastric bypass, and Roux-en-Y gastric bypass (RYGB) have been reported for treatment of severe hypothalamic obesity in craniopharyngioma patients. In a review of treatment strategies for hypothalamic obesity, van Iersel et al (4) analyzed the response to different bariatric procedures in craniopharyngioma patients and observed that 19 of 24 (79%) patients achieved a weight loss after bariatric intervention. The specific rate of responders to bariatric procedures was 0% (0 of 4) for LAGB, 100% (6 of 6) for SG, and 93% (13 of 14) for gastric bypass. Two nonresponders to bariatric interventions were observed: 1 patient after SG and 1 patient after RYGB. Van Santen et al (5) recently compared the effects and tolerability of 2 options for bariatric surgery (SG and RYGB) in craniopharyngioma patients suffering from hypothalamic obesity with body mass index–matched controls in a retrospective case-control study. No major changes in endocrine replacement therapy were observed after bariatric surgery. One patient died of unknown cause. One patient had long-term absorptive problems. Obese patients with craniopharyngioma had a substantial mean weight loss of 22% at 5 years after bariatric surgery, independent of type of bariatric surgery procedure. Weight loss was lower than in obese controls after RYGB. The authors conclude that bariatric surgery appears to be effective and relatively safe in the treatment of obese craniopharyngioma patients. This is the first study on the long-term effects of SG and RYGB in craniopharyngioma patients and matched controls. Different degrees of wei
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Bariatric interventions demonstrated notable effectiveness in weight loss and safety in patients with CP (152-154).”
From Management of Acquired Hypothalamic Dysfunction and the Hypothalamic Syndrome; It Is More Than Obesity (2025) · cites this paper as [154]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 8
- Otte, 2021, Childhood-onset craniopharyngioma, J Clin Endocrinol Metab, 10.1210/clinem/dgab397 · DOI
- Sterkenburg, 2015, Survival, hypothalamic obesity, and neuropsychological/psychosocial status after childhood-onset craniopharyngioma: newly reported long-term outcomes, Neuro Oncol., 17, 1029, 10.1093/neuonc/nov044 · DOI · Paper page
- Hoffmann, 2014, Diencephalic syndrome in childhood craniopharyngioma–results of German multicenter studies on 485 long-term survivors of childhood craniopharyngioma, J Clin Endocrinol Metab., 99, 3972, 10.1210/jc.2014-1680 · DOI · Paper page
- van Iersel, 2019, Pathophysiology and individualized treatment of hypothalamic obesity following craniopharyngioma and other suprasellar tumors: a systematic review, Endocr Rev., 40, 193, 10.1210/er.2018-00017 · DOI · Paper page
- van Santen, 2021, Bariatric surgery for hypothalamic obesity in craniopharyngioma patients: a retrospective, matched case-control study, J Clin Endocrinol Metab, 10.1210/clinem/dgab518 · DOI
- Peterli, 2012, Metabolic and hormonal changes after laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy: a randomized, prospective trial, Obes Surg., 22, 740, 10.1007/s11695-012-0622-3 · DOI · Paper page
- Bretault, 2016, Postprandial GLP-1 secretion after bariatric surgery in three cases of severe obesity related to craniopharyngiomas, Obes Surg., 26, 1133, 10.1007/s11695-015-1977-z · DOI
- Styne, 2017, Pediatric obesity-assessment, treatment, and prevention: an endocrine society clinical practice guideline, J Clin Endocrinol Metab., 102, 709, 10.1210/jc.2016-2573 · DOI · Paper page
Cited by
Müller, H. L., Tauber, M., Lawson, E. A., Özyurt, J., Bison, B., Martinez-Barbera, J.-P., Puget, S., Merchant, T. E., & van Santen, H. M. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00351-z · Cited by 144
van Santen, H. M., & Müller, H. L. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf025 · Cited by 21
(2025) · Advances in Cancer Research · doi:10.1016/bs.acr.2025.09.005 · Cited by 5
Metadata
- Authors
- Müller, H. L.
- Affiliations
- University Children’s Hospital, Department of Pediatrics and Pediatric Hematology/Oncology, Klinikum Oldenburg AöR, Carl von Ossietzky University, 26133 Oldenburg, Germany
- ORCID
- Müller, Hermann L
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2021-07-31
- Volume
- 107
- Issue
- 1
- Pages
- e426-e428
- ISSN
- 0021-972X
- 1945-7197
- Cited by
- 10
- References
- 0
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bariatric Interventions in Craniopharyngioma Patients—Best Choice or Last Option for Treatment of Hypothalamic Obesity? https://app.cochat.ai/papers/10.1210/clinem/dgab567
- The paper
- Müller, H. L. (2022). Bariatric Interventions in Craniopharyngioma Patients—Best Choice or Last Option for Treatment of Hypothalamic Obesity? The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgab567
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.